Cutler Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Cutler Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-200	Closed	-$5K	–	5023
2018 Q4	$5K	Sell	200 -400	-67%	-$5.2K	﹤0.01%	2971
2018 Q3	$12K	Buy	600 +300	+100%	+$7.04K	﹤0.01%	2569
2018 Q2	$4K	Sell	300 -700	-70%	-$19.4K	﹤0.01%	3306
2018 Q1	$7K	Sell	1,000 -3,500	-78%	-$110K	﹤0.01%	3101
2017 Q4	$6K	Sell	4,500 -2,500	-36%	-$69.8K	﹤0.01%	3554
2017 Q3	$5K	Buy	+7,000	New	+$128K	﹤0.01%	4463
2016 Q4	–	Sell	-7,600	Closed	-$18K	–	7622
2016 Q3	$18K	Buy	+7,600	New	+$116K	﹤0.01%	3555

Cutler Group's ADMS Position: Q4 2021 in Review

Cutler Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,100 shares — an estimated $5K sold.

Cutler Group first reported a position in ADMS in Q2 2016 and held it in 18 quarters. The position peaked at $144K in Q2 2016. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Cutler Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 1,100 Adamas Pharmaceuticals shares in Q4 2021, an estimated $5K.
Cutler Group first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 18 quarters.
Cutler Group's Adamas Pharmaceuticals position peaked at $144K in Q2 2016.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.